Zacks Investment Management purchased a new position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 27,701 shares of the company's stock, valued at approximately $631,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of PHR. Versor Investments LP purchased a new stake in Phreesia in the third quarter worth about $694,000. Sei Investments Co. lifted its position in Phreesia by 135.3% during the second quarter. Sei Investments Co. now owns 165,327 shares of the company's stock valued at $3,505,000 after purchasing an additional 95,058 shares during the period. Peregrine Capital Management LLC lifted its stake in shares of Phreesia by 11.3% in the 2nd quarter. Peregrine Capital Management LLC now owns 354,607 shares of the company's stock worth $7,518,000 after purchasing an additional 36,047 shares during the period. Deerfield Management Company L.P. Series C bought a new stake in shares of Phreesia during the 2nd quarter valued at $4,078,000. Finally, Essex Investment Management Co. LLC raised its stake in shares of Phreesia by 44.7% in the third quarter. Essex Investment Management Co. LLC now owns 117,849 shares of the company's stock worth $2,686,000 after buying an additional 36,406 shares during the period. Institutional investors own 92.10% of the company's stock.
Phreesia Price Performance
PHR stock traded up $0.64 during trading on Wednesday, hitting $24.78. The stock had a trading volume of 904,922 shares, compared to its average volume of 450,535. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77. The company's 50-day moving average price is $20.29 and its two-hundred day moving average price is $21.76. The stock has a market capitalization of $1.43 billion, a P/E ratio of -13.91 and a beta of 0.98. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16.
Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The business had revenue of $106.80 million during the quarter, compared to analysts' expectations of $106.33 million. During the same period in the prior year, the business earned ($0.58) earnings per share. The company's quarterly revenue was up 16.6% compared to the same quarter last year. As a group, research analysts predict that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on PHR shares. JPMorgan Chase & Co. boosted their target price on shares of Phreesia from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Monday, September 9th. DA Davidson restated a "buy" rating and set a $32.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Needham & Company LLC reissued a "buy" rating and set a $29.00 target price on shares of Phreesia in a research report on Tuesday. Truist Financial boosted their price target on Phreesia from $31.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $23.00 price target on shares of Phreesia in a research report on Friday, September 27th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.33.
View Our Latest Stock Report on Phreesia
Insider Activity
In related news, CEO Chaim Indig sold 3,089 shares of the company's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total transaction of $64,961.67. Following the sale, the chief executive officer now directly owns 1,220,647 shares of the company's stock, valued at $25,670,206.41. This represents a 0.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Allison C. Hoffman sold 1,212 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total transaction of $25,488.36. Following the completion of the sale, the general counsel now directly owns 119,791 shares in the company, valued at approximately $2,519,204.73. This trade represents a 1.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,569 shares of company stock valued at $1,123,014. 5.80% of the stock is currently owned by insiders.
Phreesia Company Profile
(
Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Further Reading
Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.